# An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

> **NCT04268966** · PHASE2 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Ebola Virus Disease

## Interventions

- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT04268966
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268966, "An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04268966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*